Company intelligence / Profile preview

Akiram Therapeutics

Ownership: Private
Development stage: Phase 1

Overview

Akiram's lead drug candidate 177Lu-AKIR001 was cleared to start Phase 1 clinical trial in October 2024 by the Swedish Medical Products Agency. The trial is registered as NCT06639191 and is being conducted in collaboration with Karolinska University Hospital. The drug has shown promising preclinical results in cancer models for conditions that currently lack effective treatments.[6][9]

Therapeutic areas: Oncology
Modalities: RadioimmunotherapyTargeted molecular radiotherapyRadiopharmaceuticals
Industry: Biotech

Drug pipeline

1 asset

lutetium-177 AKIR001

Partnerships

PreTTTetraKit TechnologiesKarolinska University Hospital

Beyond the preview

Go deeper on Akiram Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akiram Therapeutics.

Explore the full profile